HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option.

AbstractBACKGROUND:
The mammalian target of rapamycin (mTOR) pathway inhibition has emerged as one of the main directions for the development of new targeted agents in renal cell carcinoma (RCC). A prominent member in its class of medications, temsirolimus has already been shown to improve overall survival in advanced kidney cancer, when compared with the previous standard, IFN-alpha.
OBJECTIVE:
The aim of this study was to review the most relevant preclinical and clinical data on the mTOR inhibitors, both in clinical use or in current development.
METHODS:
The authors give a comprehensive review of the existing English literature on the role of the mTOR pathway in renal tumorigenesis, as well as a detailed safety and efficacy analysis of older and newer rapamycin analogs.
RESULTS/CONCLUSIONS:
Rapamycin derivatives temsirolimus and everolimus have significant clinical activity in patients with advanced-stage RCC. Both parenteral and oral formulations of mTOR inhibitors have shown clinical efficacy and are currently being developed. Combinations of mTOR inhibitors with VEGF/VEGFR-blocking agents are also being studied, in an attempt to further enhance the antineoplastic effect.
AuthorsConstantin A Dasanu, Bernard A Clark 3rd, Doru T Alexandrescu
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 18 Issue 2 Pg. 175-87 (Feb 2009) ISSN: 1744-7658 [Electronic] England
PMID19236264 (Publication Type: Journal Article, Review)
Chemical References
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus
Topics
  • Animals
  • Antibiotics, Antineoplastic (pharmacology, therapeutic use)
  • Antineoplastic Agents (adverse effects, pharmacology, therapeutic use)
  • Carcinoma, Renal Cell (drug therapy)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Hypophosphatemia (chemically induced)
  • Kidney Neoplasms (drug therapy)
  • Protein Kinases (drug effects, physiology)
  • Signal Transduction (drug effects, physiology)
  • Sirolimus (analogs & derivatives, pharmacology, therapeutic use)
  • TOR Serine-Threonine Kinases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: